Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 3, 2009, Pages 470-474

  Chen, Shih Fen ^a   Shen, Yu Chih ^b,c   Chen, Chia Hsiang ^b,c  

^a NATIONAL DONG HWA UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Aripiprazole; Dopamine D3 receptor; DRD3 Ser9Gly polymorphism

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; GLYCINE; SERINE;

ADULT; AGE; ARTICLE; CHINESE; CLINICAL FEATURE; DISEASE DURATION; DRD3 GENE; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; FEMALE; GENOTYPE; GLYCINE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; PIPERAZINES; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; RECEPTORS, DOPAMINE D3; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SERINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 62849115890     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.01.007     Document Type: Article

References (30)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed (2000) Washington, DC
2. Barlas I.O., Cetin M., Erdal M.E., Semiz U.B., Basoglu C., Ay M.E., et al. Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizophrenia patients. Am J Med Genet B Neuropsychiatr Genet (2008) [Epub ahead of print]
3. Buchner A., Faul F., and Erdfelder E. G-power: a priori, post hoc, and compromise power analyses for the Macintosh (1996) version 2.1.1.
4. Chouinard G., and Margolese H.C. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 76 (2005) 247-265
5. Conley R.R., Carpenter Jr. W.T., and Tamminga C.A. Time to clozapine response in a standardized trial. Am J Psychiatry 154 (1997) 1243-1247
6. Ebstein R.P., Macciardi F., Heresco-Levi U., Serretti A., Blaine D., Verga M., et al. Evidence for an association between the dopamine D3 receptor gene DRD3 and schizophrenia. Hum Hered 47 (1997) 6-16
7. Gurevich E.V., and Joyce J.N. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol Psychiatry 42 (1997) 529-545
8. Jeanneteau F., Funalot B., Jankovic J., Deng H., Lagarde J.P., Lucotte G., et al. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci 103 (2006) 10753-10758
9. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 261-276
10. Kikuchi T., Tottori K., Uwahodo Y., Hirose T., Miwa T., Oshiro Y., et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 274 (1995) 329-336
11. Lane H.Y., Hsu S.K., Liu Y.C., Chang Y.C., Huang C.H., and Chang W.H. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J Clin Psychopharmacol 25 (2005) 6-11
12. Lane H.Y., Lee C.C., Liu Y.C., and Chang W.H. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics. Pharmacogenomics 6 (2005) 139-149
13. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., and Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334 (1987) 1-100
14. Lundstrom K., and Turpin M.P. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 225 (1996) 1068-1072
15. Malhotra A.K., and Goldman D. Benefits and pitfalls encountered in psychiatric genetic association studies. Biol Psychiatry 45 (1999) 544-550
16. Malhotra A.K., Goldman D., Buchanan R.W., Rooney W., Clifton A., Kosmidis M.H., et al. The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. Mol Psychiatry 3 (1998) 72-75
17. Malhotra A.K., Murphy Jr. G.M., and Kennedy J.L. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161 (2004) 780-796
18. Mojtabai R. Duration of illness and structure of symptoms in schizophrenia. Psychol Med 29 (1999) 915-924
19. Raja M. Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole. Int J Neuropsychopharmacol 1 (2006) 1-4
20. Reeves R.R., and Mack J.E. Worsening schizoaffective disorder with aripiprazole. Am J Psychiatry 161 (2004) 1308
21. Reynolds G.P., Yao Z., Zhang X., Sun J., and Zhang Z. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol 15 (2005) 143-151
22. Scharfetter J., Chaudhry H.R., Hornik K., Fuchs K., Sieghart W., Kasper S., et al. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients. Eur Neuropsychopharmacol 10 (1999) 17-20
23. Shaikh S., Collier D.A., Sham P.C., Ball D., Aitchison K., Vallada H., et al. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Genet 97 (1996) 714-719
24. Shen Y.C., Chen S.F., Chen C.H., Lin C.C., Chen S.J., Chen Y.J., et al. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. J Psychiatr Res (2008) 10.1016/j.jpsychires.2008.09.005
25. Sokoloff P., Giros B., Martres M.P., Andrieux M., Besancon R., Pilon C., et al. Localization and function of the D3 dopamine receptor. Arzneimittelforschung 42 (1992) 224-230
26. Staddon S., Arranz M.J., and Mancama D. Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology 162 (2002) 18-23
27. Szekeres G., Keri S., Juhasz A., Rimanoczy A., Szendi I., Czimmer C., et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 124 (2004) 1-5
28. Uzun S., Kozumplik O., Mimica N., and Folnegovic-Smalc V. Aripiprazole: an overview of a novel antipsychotic. Psychiatr Danub 17 (2005) 67-75
29. Xuan J., Zhao X., He G., Yu L., Wang L., Tang W., et al. Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study. Neuropsychopharmacology 33 (2008) 305-311
30. Yokoi F., Grunder G., Biziere K., Stephane M., Dogan A.S., Dannals R.F., et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27 (2002) 248-259